BEAM THERAPEUTICS INC (BEAM) Stock Fundamental Analysis

NASDAQ:BEAM • US07373V1052

28.46 USD
-0.46 (-1.59%)
At close: Feb 27, 2026
27.95 USD
-0.51 (-1.79%)
After Hours: 2/27/2026, 5:01:40 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, BEAM scores 3 out of 10 in our fundamental rating. BEAM was compared to 521 industry peers in the Biotechnology industry. BEAM has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, BEAM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year BEAM has reported negative net income.
  • In the past year BEAM has reported a negative cash flow from operations.
  • In the past 5 years BEAM always reported negative net income.
  • In the past 5 years BEAM reported 4 times negative operating cash flow.
BEAM Yearly Net Income VS EBIT VS OCF VS FCFBEAM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -31.63%, BEAM is in the better half of the industry, outperforming 65.26% of the companies in the same industry.
  • BEAM's Return On Equity of -42.92% is fine compared to the rest of the industry. BEAM outperforms 69.48% of its industry peers.
Industry RankSector Rank
ROA -31.63%
ROE -42.92%
ROIC N/A
ROA(3y)-21.59%
ROA(5y)-26.65%
ROE(3y)-34.76%
ROE(5y)-45.77%
ROIC(3y)N/A
ROIC(5y)N/A
BEAM Yearly ROA, ROE, ROICBEAM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

  • BEAM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BEAM Yearly Profit, Operating, Gross MarginsBEAM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • BEAM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BEAM has more shares outstanding than it did 1 year ago.
  • BEAM has more shares outstanding than it did 5 years ago.
  • BEAM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BEAM Yearly Shares OutstandingBEAM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
BEAM Yearly Total Debt VS Total AssetsBEAM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • BEAM has an Altman-Z score of 2.79. This is not the best score and indicates that BEAM is in the grey zone with still only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.79, BEAM is in the better half of the industry, outperforming 66.60% of the companies in the same industry.
  • BEAM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.79
ROIC/WACCN/A
WACC8.66%
BEAM Yearly LT Debt VS Equity VS FCFBEAM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 6.02 indicates that BEAM has no problem at all paying its short term obligations.
  • The Current ratio of BEAM (6.02) is better than 62.38% of its industry peers.
  • BEAM has a Quick Ratio of 6.02. This indicates that BEAM is financially healthy and has no problem in meeting its short term obligations.
  • BEAM has a Quick ratio of 6.02. This is in the better half of the industry: BEAM outperforms 63.72% of its industry peers.
Industry RankSector Rank
Current Ratio 6.02
Quick Ratio 6.02
BEAM Yearly Current Assets VS Current LiabilitesBEAM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for BEAM have decreased strongly by -151.70% in the last year.
  • Looking at the last year, BEAM shows a very negative growth in Revenue. The Revenue has decreased by -84.07% in the last year.
  • BEAM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 401.62% yearly.
EPS 1Y (TTM)-151.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.98%
Revenue 1Y (TTM)-84.07%
Revenue growth 3Y7.01%
Revenue growth 5Y401.62%
Sales Q2Q%-32.03%

3.2 Future

  • The Earnings Per Share is expected to grow by 6.38% on average over the next years.
  • Based on estimates for the next years, BEAM will show a very strong growth in Revenue. The Revenue will grow by 50.43% on average per year.
EPS Next Y6.47%
EPS Next 2Y-1.92%
EPS Next 3Y-1.48%
EPS Next 5Y6.38%
Revenue Next Year-25.2%
Revenue Next 2Y-4.45%
Revenue Next 3Y5.7%
Revenue Next 5Y50.43%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BEAM Yearly Revenue VS EstimatesBEAM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
BEAM Yearly EPS VS EstimatesBEAM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BEAM. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BEAM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BEAM Price Earnings VS Forward Price EarningsBEAM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BEAM Per share dataBEAM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.92%
EPS Next 3Y-1.48%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BEAM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BEAM THERAPEUTICS INC

NASDAQ:BEAM (2/27/2026, 5:01:40 PM)

After market: 27.95 -0.51 (-1.79%)

28.46

-0.46 (-1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-03
Inst Owners102.13%
Inst Owner Change2.77%
Ins Owners1.21%
Ins Owner Change-1.56%
Market Cap2.89B
Revenue(TTM)55.70M
Net Income(TTM)-414.64M
Analysts86.67
Price Target47.45 (66.73%)
Short Float %19.36%
Short Ratio10.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.96%
Min EPS beat(2)-3.72%
Max EPS beat(2)11.65%
EPS beat(4)2
Avg EPS beat(4)4.61%
Min EPS beat(4)-3.72%
Max EPS beat(4)11.65%
EPS beat(8)6
Avg EPS beat(8)38.34%
EPS beat(12)10
Avg EPS beat(12)33.96%
EPS beat(16)13
Avg EPS beat(16)27.04%
Revenue beat(2)0
Avg Revenue beat(2)-31.11%
Min Revenue beat(2)-38.81%
Max Revenue beat(2)-23.41%
Revenue beat(4)1
Avg Revenue beat(4)-9.71%
Min Revenue beat(4)-50.74%
Max Revenue beat(4)74.11%
Revenue beat(8)2
Avg Revenue beat(8)180.25%
Revenue beat(12)5
Avg Revenue beat(12)131.05%
Revenue beat(16)9
Avg Revenue beat(16)242.98%
PT rev (1m)2.32%
PT rev (3m)0.97%
EPS NQ rev (1m)1.63%
EPS NQ rev (3m)14.63%
EPS NY rev (1m)3.2%
EPS NY rev (3m)3.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.94%
Revenue NY rev (1m)3.56%
Revenue NY rev (3m)-8.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 51.85
P/FCF N/A
P/OCF N/A
P/B 2.99
P/tB 2.99
EV/EBITDA N/A
EPS(TTM)-4.43
EYN/A
EPS(NY)-4.76
Fwd EYN/A
FCF(TTM)-3.47
FCFYN/A
OCF(TTM)-3.33
OCFYN/A
SpS0.55
BVpS9.52
TBVpS9.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.63%
ROE -42.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.59%
ROA(5y)-26.65%
ROE(3y)-34.76%
ROE(5y)-45.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.26%
Cap/Sales 25.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.02
Quick Ratio 6.02
Altman-Z 2.79
F-Score3
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)185.1%
Cap/Depr(5y)305.75%
Cap/Sales(3y)34.46%
Cap/Sales(5y)16398.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-151.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.98%
EPS Next Y6.47%
EPS Next 2Y-1.92%
EPS Next 3Y-1.48%
EPS Next 5Y6.38%
Revenue 1Y (TTM)-84.07%
Revenue growth 3Y7.01%
Revenue growth 5Y401.62%
Sales Q2Q%-32.03%
Revenue Next Year-25.2%
Revenue Next 2Y-4.45%
Revenue Next 3Y5.7%
Revenue Next 5Y50.43%
EBIT growth 1Y-155.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.01%
EBIT Next 3Y-8.69%
EBIT Next 5Y7.25%
FCF growth 1Y10.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.33%
OCF growth 3YN/A
OCF growth 5YN/A

BEAM THERAPEUTICS INC / BEAM FAQ

What is the ChartMill fundamental rating of BEAM THERAPEUTICS INC (BEAM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BEAM.


Can you provide the valuation status for BEAM THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to BEAM THERAPEUTICS INC (BEAM). This can be considered as Overvalued.


Can you provide the profitability details for BEAM THERAPEUTICS INC?

BEAM THERAPEUTICS INC (BEAM) has a profitability rating of 1 / 10.


How financially healthy is BEAM THERAPEUTICS INC?

The financial health rating of BEAM THERAPEUTICS INC (BEAM) is 7 / 10.


What is the earnings growth outlook for BEAM THERAPEUTICS INC?

The Earnings per Share (EPS) of BEAM THERAPEUTICS INC (BEAM) is expected to grow by 6.47% in the next year.